Pfizer remains in focus as oncology partnerships, colorectal cancer research developments, and pharmaceutical innovation ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

Pfizer (PFE) is back in focus after two R&D milestones, a broader European indication for hemophilia drug HYMPAVZI and ...

NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, ...

London — U.S. drugmaker Pfizer said Monday that human trials suggest its coronavirus vaccine is 90% effective at preventing COVID-19 infections in people not known to have had the virus already. The ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...

NEW YORK, N.Y. — Pfizer and BioNTech announced Friday that they’re submitting new data to the Food and Drug Administration (FDA) that shows their COVID-19 vaccine can be stored at higher temperatures, ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the ...